The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...

ABSTRACT: Background: Diabetes Mellitus (DM) is the leading cause of Visual Impairment (VI) globally and VI is the most common and debilitating complication of DM; it significantly impacts the quality ...

Department of Ophthalmology, National Taiwan University Hospital, Hsinchu Branch, Hsinchu 302, Taiwan Department of Ophthalmology, National Taiwan University Hospital, Taipei 100, Taiwan Graduate ...

Some reassuring news for patients taking GLP-1 receptor agonists: Concerns that the drugs may cause retinopathy may be overblown. A new analysis of nearly 160,000 people with diabetes taking four ...

ABSTRACT: Objective: To evaluate the impact of current and emerging biologic therapies on the treatment of diabetic eye diseases, specifically diabetic retinopathy and diabetic macular edema, and to ...

Survival models using EHR data predicted progression from NPDR or DME to PDR in type 2 diabetes patients. Key risk factors for progression included age, race, NPDR severity, and diabetic nephropathy.